DYF1 Stock Overview
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for DYF1 from our risk checks.
Dynavax Technologies Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.99 |
| 52 Week High | US$14.01 |
| 52 Week Low | US$9.18 |
| Beta | 1.28 |
| 1 Month Change | -2.01% |
| 3 Month Change | -15.00% |
| 1 Year Change | 13.42% |
| 3 Year Change | 36.12% |
| 5 Year Change | 86.62% |
| Change since IPO | -63.85% |
Recent News & Updates
Recent updates
Shareholder Returns
| DYF1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 1.2% | -5.1% | -2.0% |
| 1Y | 13.4% | -21.1% | -0.3% |
Return vs Industry: DYF1 exceeded the German Biotechs industry which returned -21.1% over the past year.
Return vs Market: DYF1 exceeded the German Market which returned -0.3% over the past year.
Price Volatility
| DYF1 volatility | |
|---|---|
| DYF1 Average Weekly Movement | 4.2% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: DYF1 has not had significant price volatility in the past 3 months.
Volatility Over Time: DYF1's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 408 | Ryan Spencer | www.dynavax.com |
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B.
Dynavax Technologies Corporation Fundamentals Summary
| DYF1 fundamental statistics | |
|---|---|
| Market cap | €1.45b |
| Earnings (TTM) | -€6.00m |
| Revenue (TTM) | €217.98m |
6.7x
P/S Ratio-242.5x
P/E RatioIs DYF1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DYF1 income statement (TTM) | |
|---|---|
| Revenue | US$232.28m |
| Cost of Revenue | US$102.48m |
| Gross Profit | US$129.81m |
| Other Expenses | US$136.19m |
| Earnings | -US$6.39m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.049 |
| Gross Margin | 55.88% |
| Net Profit Margin | -2.75% |
| Debt/Equity Ratio | 35.8% |
How did DYF1 perform over the long term?
See historical performance and comparison